Is the price fair?
What PTGX's price assumes
Protagonist Therapeutics, Inc. trades at 143× earnings against 31.5× for the median Biotechnology name, more expensive than its own group.
143
Trailing P/E · Biotechnology median 31.5 · 4.54× the median: the market pays up for this one
- Price / sales
- 100
Price / sales · as of 2026-Q1
- Free cash flow yield
- 1.7%
Free cash flow yield · Biotechnology median 2.4%
- Growth the price implies
- +20%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
Details›
- Price / book2026-Q1
- 11.3
- Healthcare median P/E362 names
- 29.9
- Biotechnology median P/E158 names
- 31.5
- Free cash flow, trailing twelve months
- $131M
- Market capitalisation
- $7.89B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.